Astatine-211 for targeted alpha therapy – current status and future perspectives
Focused Pre-Symposium organized by the COST action NOAR
Thursday, April 18 from 16:00-18:00
Welcome & Introduction by the ESRR local organizers – Antero Abrunhosa
The current status of astatine research, production & clinical trials at brief – Emma Aneheim, COST-NOAR Vice Chair
Scientific presentation 1: “Preparation and evaluation of stabilized 211At-labelled aryl compounds” – Romain Fouinneteau, France
Scientific presentation 2: “Defining a time-yield correlation of two different radiolabelling strategies using Astatine-211 recovered in chloroform after dry distillation” – Ellinor Hansson, Sweden
Scientific presentation 3: “Astatinations via Germanyl Precursors – A new convient labeling method” – Mattias Herth, Denmark
Future perspectives of astatine-211 use within TAT; introducing the World Astatine Community – Jean-François Gestin, COST-NOAR Chair
Scientific Programme – ESRR’24
Download the PDF Version here:
Thursday, April 18, 2024
| 19:30 – 20:30 | Opening Ceremony & Welcome meeting Chairpersons: Antero Abrunhosa, Filippo Lodi AI in chemistry, with focus on data-driven reaction prediciton Teodoro Laino, Zurich, CH |
Friday, April 19, 2024
| Sci Session 1 | Imaging tracers Chairpersons: Jessica Bridoux, Filipe Elvas |
| 08:30 – 09:15 | Back-to-basics I: Novel agents and future prespectives on theranostics Filipe Elvas, Antwerp, BE |
| 09:15 – 09:27 | Oral Sessions: OP01 Improved PET imaging of NETs with [61Cu]-NOTA-TATE: a straightforward comparison with [61Cu]-/[68Ga]-DOTA-TATE Alexandra Fonseca, PT |
| 09:27 – 09:39 | OP02 Development of SPECT agent [99mTc]Tc-BQ0413 for PSMA visualization: preclinical evaluation and preliminary results of Phase I clinical study Anna Orlova, SE |
| 09:39 – 09:51 | OP03 Folate-targeted polymeric micelles for image-guided drug delivery of an anticancer gold complex Joana Santos, PT |
| 09:51-10:03 | OP04 Development and characterization of 99mTc-scFvD2B as a potential theranostic pair for 177Lu-scFvD2B Laura Melendez Alafort , IT |
| 10:05 – 10:35 | Coffee Break |
| Sci Session 2 | Auger and other therapeutic emitters Chairpersons: Peter Laverman, Samantha Terry |
| 10:35 – 11:20 | Auger electron therapy Samantha Terry, London, UK |
| 11:20 – 11:32 | Oral Sessions: OP05 111In- and 161Tb-Radioconjugates Carrying PSMA and Triphenylphosphonium Derivatives for Auger Therapy of Prostate Cancer António Paulo, PT |
| 11:32 – 11:44 | OP06 Sulfur Symphony: Capturing the Exotic Mercury-197m/g Auger Emitters with Macrocyclic S-Rich Chelators Marianna Tosato, Italy |
| 11:44 – 11:56 | OP07 Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97/103 Thomas Mindt, AT |
| 11:56 – 12:08 | OP08 Nanobioconjugates of 109Pd/109mAg in-vivo generators for targeted Auger electron therapy Aleksander Bilewicz, PL |
| 12:08 – 12:20 | OP09 Synthesis, 68Ga-radiolabelling and in vitro evaluation of a PET/PDT agent for prostate cancer theranostics Laurène Wagner, UK |
| 12:20 – 13:45 | Lunch |
| Sci Session 3 | New oncological radiotracers Chairpersons: Sanne van Lith, Ines Farinha Antunes |
| 13:45 – 14:30 | Improving radioimmunotherapy with immuno/chemotherapy/EBRT – a winning combination? Sanne van Lith, Nijmegen, NL |
| 14:30 – 14:42 | Oral Sessions: OP10 Structure-based design, optimization and development of [18F]SK60: A Novel PET radioligand for the imaging of mutated Isocitrate Dehydrogenase Sarandeep Kaur, DE |
| 14:42 – 14:54 | OP11 Molecular Imaging of HER2 Expression in Breast Cancer Using DARPin [123I]I-(HE)3-G3. From mice to Phase I. Vladimir Tolmachev, SE |
| 14:54 – 15:06 | OP12 Fully automated production of [18F]FB-labeled single-domain antibodies: the immune-checkpoint TIGIT for PET imaging Herlinde Dierick, BE |
| 15:06 – 15:18 | OP13 A novel Al18F-labeled radiotracer for in vivo imaging of CXCR4 using positron emission tomography Muriel Aline Spahn, BE |
| 15:18 – 15:30 | OP14 Radioiodinated closo-dicarbadodecaborane(12)-based cyclooxygenase-2/5-lipoxygenase inhibitors Jonas Schädlich, DE |
| 15:30 – 16:00 | Coffee Break |
| Sci Session 4 | Chairpersons: Martin Behe, Thomas Mindt |
| 16:00 – 16:45 | Debate: Small molecules vs peptides vs antibodies vs antibody fragments as vector molecule for theranostic radiopharmaceuticals Moderator: Frederik Cleeren, Leuven, BE |
| 16:45 – 17:15 | Poster pitches (order of presentation) PP34 89Zr-DFO-Atezolizumab for PD-L1 Imaging of Glioblastoma: Clinical Experience Anna Kastelik-Hryniewiecka PP43 211At-labeling of trans-cyclooctenes and cis-cyclooctenes with astatine-211 using electrophilic and nucleophilic reactions Maarten Vanermen PP46 Manufacturing of investigational medicinal products under GMP conditions using the example of a radiopharmaceutical kit PSMA-T4 for technetium-99m labelling Anna Drapsa PP47 Radionuclidic purity of Ga-68 eluted from Ge-68/Ga-68 generators by Thin Layer Chromatography Joao Alberto Osso Junior PP53 Preliminary evaluation of a novel Temozolomide-based molecule radiolabeled with 99mTc as a theranostic agent against glioblastoma Penelope Bouziotis PP54 PSMA-targeted Radioconjugates Bearing a DNA Intercalator for Enhanced Auger Therapy of Prostate cancer Catarina Dorisa Silva PP55 Therapeutic Efficacy of 177Lu-DMSA-SPIONs in a Mouse CT26 and 4T1 Xenograft Model Dragana Stanković PP57 Automated production of [68Ga]Ga-deferoxamine on two different synthesis modules for bacterial infection imaging Martin Kraihammer PP61 Development of [18F]AlF-RESCA-FSH as a diagnostic probe for ovarian cancer Maria Kominia PP63 Using Epin boronic esters as substrates improves the copper-mediated [18F]-fluorination of arenes Annemarie Doze |
| 17:15 – 18:00 | Poster viewing + refreshments |
Saturday, April 20, 2024
| Sci Session 5 | Radiochemistry Chairpersons: Matthias Herth, Verena Pichler |
| 08:30 – 09:15 | Back-to-basics II: Computational methods in radiopharmaceutical sciences Verena Pichler, Vienna, AT |
| 09:15 – 09:27 | Oral Sessions: OP15 Synthesis, stability determination and radiolabeling of new diazabenzene-based azamacrocycles with barium-131, actinium-225, lanthanum-133, and lead-212 Magdalena Blei, DE |
| 09:27 – 09:39 | OP16 Evaluation of sydnones-based click chemistry for the labeling with heavy radiohalogens Ludovic Le Saux, FR |
| 09:39 – 09:51 | OP17 From Theory to Clinical Application: Understanding Ac-225 radiochemistry through [225Ac]Ac-DOTA-TATE Eline Hooijman, NL |
| 09:51 – 10:05 | OP18 Radiolabelling of various macrocyclic ligands using 155Tb/156Tb radioisotopes Mátyás Fodor, HU |
| 10:05 – 10:35 | Coffee Break |
| Sci Session 6 | New neurological tracers Chairpersons: Philip Elsinga, Bienke Janssen |
| 10:35 – 11:20 | Pretargeting strategies, where are we? Matthias Herth, Copenhagen, DN |
| 11:20 – 11:32 | Oral Sessions: OP19 11C-carboxylations using Grignard reactions for the preparation of [carbonyl 11C]WAY-100635 and [1-11C]Sodium Acetate Vanessa Tomé, PT |
| 11:32 – 11:44 | OP20 Preclinical evaluation of [11C]HSP990 as novel Hsp90 PET brain probe for in vivo visualization of Hsp90 in healthy aging and neurodegeneration Romy Cools, BE |
| 11:44 – 11:56 | OP21 Radiolabeling of M13 bacteriophages for in vivo imaging Johanna Trommer, DE |
11:56 – 12:08 | OP22 Synthesis, in vitro and in vivo evaluation of novel radioligands for α-synuclein PET Albert D. Windhorst, NL |
| 12:08 – 13:00 | Workshop: EATRIS EU Tracer Factory Nadja van Camp Bert Windhorst |
| 13:00 – 14:00 | Lunch |
| Sci Session 7 | New infection and inflammation tracers Chairpersons: Aljaz Socan, Jan Rijn Zeevaart |
| 14:00 – 14:42 | Tracking cells with radiopharmaceuticals: strategies and applications Aljaž Sočan, Ljubljana, SL |
| 14:42 -14:54 14:54 – 15:06 15:06 – 15:18 15:18 – 15:30 | Oral Sessions: OP23 Repurposing a pharmaceutical development for infection theranostics Clemens Decristoforo, AT OP24 Synthesis and preclinical evaluation of novel 18F-vancomycin-based tracers for the detection of bacterial infections using positron emission tomography Gerbren B. Spoelstra, NL OP25 Artificial biomimetic Siderophores as PET radiopharmaceuticals: Radiolabelling and evaluation for PET imaging of invasive aspergillosis Milos Petrik, CZ OP26 [68Ga]Ga-TEoS-DAZA as PET tracer for liver function determination and diagnosis of liver-bile-related diseases Julia Greiser, DE |
| 15:30 – 16:00 | Coffee Break |
| Sci Session 8 | Chairpersons: Petra Kolenc, Clemens Decristoforo |
| 16:00 – 17:00 | Round table GMP and Legislation (Annex 1 and 3) Problems arising from revised Annex 1 for preparation of radiopharmaceuticals Thijs Kroon, Amsterdam, NL A pharmacist’s view on practical problems with Annex 1 for PET Hendrikus Boersma, Groningen, NL Practical problems with Annex 1 for kit-based Radiopharmaceuticals and how a revision of Annex 3 help with the issues Neil Hartman, Swansea, UK Outcome from an ITF EMA meeting of PRISMAP (quality requirements for new radionuclides in clinical trials) Oliver Kiss, Dresden, DE Questions from PRISMAP on Annex 3, will it be revised and what can we do? Clemens Decristoforo, Innsbruck, AT Discussion |
| 17:00 – 18:00 | Pharmacopoeia Corner Thijs Kroon Ellen Pel |
Sunday, April 21, 2024
| Sci Session 9 | From alpha to beta and back Chairpersons: Janke Kleynhans, Klaus Kopka |
| 08:30 – 09:15 | Back-to-basics III: Alpha emitters, from basic physics to labeling and measuring Janke Kleynhans, Leuven, BE |
| 09:15 – 09:27 | Oral Sessions : OP27 Tumor-targeted alpha therapy using terbium-149 in combination with somatostatin analogues Cristina Müller, CH |
| 09:27 – 09:39 | OP28 Synergistic effects of a combination of trastuzumab-emtansine (T-DM1) and β- radiation (198AuNPs) for targeted HER2+ therapy Agnieszka Majkowska-Pilip, PL |
09:39 – 09:51 | OP29 Assessment of cell damage produced by somatostatin analog radiopharmaceuticals labelled with 177Lu or 161Tb Laura De Nardo, IT |
| 09:51 – 10:05 | OP30 Preclinical assessment of enhanced blood retention and tumor uptake PSMA-targeting 225Ac-labeled radioconjugates Zbynek Novy, CZ |
| 10:05 – 10:35 | Coffee Break |
| Sci Session 10 | Radionuclide production Chairpersons: Nicholas van der Meulen, Tom Christian Adamsen |
| 10:35 – 10:47 | Oral Sessions: OP31 Terbium-149 production and separation: the latest development update Nicholas van der Meulen, CH |
| 10:47 – 10:59 | OP32 155Gd-target enrichment for 155Tb production by low-energy cyclotrons Francesca Barbaro, IT |
| 10:59 – 11:11 | OP33 Development of a new technology for the 52Mn-radiopharmaceuticals cyclotron production Giorgia Speltri, IT |
| 11:11 – 11:23 | OP34 An alternative production route for the PET radionuclide 61Cu: exploring the 62Ni(p,2n)61Cu nuclear reaction Santiago Brühlmann, DE |
| 11:25 – 12:15 | Closing / Awards Ceremony |
| 12:15 – 13:00 | Farewell Lunch |